Loss-of-Function Variants Associated with Gastric Cancer Risk
the Cancer Therapy Advisor take:
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer, according to an article published online in the journal Nature Genetics.
A Genome-wide association study (GWAS) in a European population with information on 2,500 cases of gastric cancer and 205,652 controls was reported.
The authors found a new association between gastric cancer and the loss-of-function mutations in ATM gene test, P = 8.0 × 10−12; OR = 4.74). Patients carrying the loss-of-function mutations were diagnosed with cancer significantly earlier in age than those not carrying the variations.
Furthermore, a combination of the loss-of-function mutations p.Gln852, p.Ser644, and p.Tyr103 (combined minor allele frequency (MAF) = 0.3%) were linked with pancreatic (OR = 3.81) and prostate (OR = 2.18) cancer and indicated a risk of breast (OR = 1.82) and colorectal (OR = 1.97) cancer.
Results confirmed a relationship between the three loci associated with gastric cancer in Asia (MUC1, PRKAA1 and PSCA) and gastric cancer in Europeans.
Loss-of-function mutations in ATM were associated with an increased risk for developing gastric cancer.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- A Vegan Diet and Cancer
- As HPV-Related Cancer Rates Climb, Experts Scrutinize Barriers to HPV Vaccination
- Bowel Preparation for Colorectal Cancer Screening: Improving Outcomes
- Tool for Assessing Frailty Predicts Survival in Newly Diagnosed Multiple Myeloma
- Analysis Supports Flat Dose of Nivolumab 480 mg Every 4 Weeks
- FDA-Approved Breast Cancer Drug Treatments
- A Trained Dog Smells Early-Stage Lung Cancer With a High Degree of Accuracy
- FDA-Approved Prostate Cancer Drug Treatments
- FDA-Approved Colorectal Cancer Drug Treatments
- Synthetic or Plant-Based Cannabis for Symptom Relief in Patients With Cancer: Do We Have Any Evidence?
- Treatment Delays May Mean Worse Survival in Head and Neck Cancer
- New Combo for Chronic Myeloid Leukemia Shows Activity In Vitro
- Age-adjusted Comorbidity Predicts Survival in Laryngeal Cancer
- Are Next-Gen Antibody-Drug Conjugates a Path Forward for Non-Hodgkin Lymphoma and Myeloma?
- Role of miR-125a-5p Clarified in Bladder Cancer